Comparative Pharmacology
Head-to-head clinical analysis: BARHEMSYS versus VONTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BARHEMSYS versus VONTROL.
BARHEMSYS vs VONTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BARHEMSYS (amisulpride) is a selective dopamine D2/D3 receptor antagonist. It also has weak affinity for serotonin 5-HT2A and 5-HT2B receptors, with no significant activity at other dopamine or serotonin receptor subtypes. Its antiemetic effect is primarily mediated through blockade of D2 receptors in the chemoreceptor trigger zone (CTZ).
VONTROL (trimethobenzamide) acts centrally to inhibit the chemoreceptor trigger zone (CTZ) in the medulla oblongata, thereby suppressing nausea and vomiting. Its exact mechanism is not fully understood but may involve antagonism of dopamine D2 receptors and serotonin 5-HT3 receptors.
BARHEMSYS (amisulpride) 10 mg intravenously over 2 minutes, once daily for prevention of postoperative nausea and vomiting.
10 mg orally twice daily; maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours, supporting once-daily dosing in most patients.
12 hours; prolonged in renal impairment (up to 24 hours in ESRD)
Renal excretion accounts for approximately 50% of the dose as unchanged drug; fecal elimination (including biliary) accounts for approximately 30-40%.
Renal: 60% unchanged; fecal: 30% (biliary); hepatic metabolism: 10%
Category C
Category C
Antiemetic
Antiemetic